Abstract
Myocardial infarction is the permanent death (necrosis) of heart muscle caused by
a lack of oxygen for an extended period of time (ischemia). Since the very first percutaneous
transluminal coronary angioplasty was done 40 years ago, the science of interventional
cardiology has advanced dramatically. The above progression began with a balloon catheter
attached to a fixed wire, advancing to bare-metal stents, first-generation drug-eluting
stents (DES), second- and third-generation biodegradable polymer-based DES. Ultimately,
bioabsorbable stents are still in development. Zotarolimus is a new pharmacologic
therapy with a similar reprint address; for example, the antirestenosis agent sirolimus
has recently been investigated as part of a stent platform combined with a biomimetic
phosphorylcholine and BioLINX polymer for its biological activity, as well as its
usefulness as an antiproliferative agent. Several clinical trials have been conducted
to assess the safety and efficacy of the zotarolimus drug-eluting stent (Z-DES). Medtronic
Medical Devices, a global leader in medical technology (United States), and Abbot
Global Health Care and Research began clinical trials on the Z-DES in 2002 and will
continue through 2021 (INDIA). Endeavor (E-Zes), Resolute (R-Zes), Resolute Integrity
(I-Zes), and Resolute Onyx are the different forms of Z-DES that Medtronic has tested
in clinical trials. In comparison to other DES, Z-DES was found to be safe in these
clinical trials done across multiple nations and in a diverse demographic. This review
helps understand the overall clinical trial of Z-DES.
Keywords
myocardial infarction - coronary artery intervention - coronary lesion - angioplasty
- restenosis - thrombosis
